Home LiteratureArticle Details
PMID: 26451317 Published · epublish English Journal Article Research Support, Non-U.S. Gov't

COX-2 promotes metastasis in nasopharyngeal carcinoma by mediating interactions between cancer cells and myeloid-derived suppressor cells.

Oncoimmunology ·Vol. 4 ·No. 11 ·2015-11-00 ·Pages e1044712

Li ZL, Ye SB, OuYang LY, Zhang H, Chen YS, He J, Chen QY, Qian CN, Zhang XS, Cui J, Zeng YX, Li J

Abstract

The expansion of myeloid-derived suppressor cells (MDSCs) is a common feature of cancer, but its biological roles and molecular mechanism remain unclear. Here, we investigated a molecular link between MDSC expansion and tumor cell metastasis in nasopharyngeal carcinoma (NPC). We demonstrated that MDSCs expanded and were positively correlated with the elevated tumor COX-2 expression and serum IL-6 levels in NPC patients. Importantly, COX-2 and MDSCs were poor predictors of patient disease-free survival (DFS). Knocking down tumor COX-2 expression hampered functional TW03-mediated-MDSC cell (T-MDSC) induction with IL-6 blocking. We identified that T-MDSCs promoted NPC cell migration and invasion by triggering the epithelial-mesenchymal transition (EMT) on cell-to-cell contact, and T-MDSCs enhanced tumor experimental lung metastasis in vivo. Interestingly, the contact between T-MDSCs and NPC cells enhanced tumor COX-2 expression, which subsequently activated the β-catenin/TCF4 pathway, resulting in EMT of the cancer cells. Blocking transforming growth factor β (TGFβ) or inducible nitric oxide synthase (iNOS) significantly abolished the T-MDSC-induced upregulation of COX-2 and EMT scores in NPC cells, whereas the administration of TGFβ or L-arginine supplements upregulated COX-2 expression and EMT scores in NPC cells. These findings reveal that COX-2 is a key factor mediating the interaction between MDSCs and tumor cells, suggesting that the inhibition of COX-2 or MDSCs has the potential to suppress NPC metastasis.

Keywords
COX-2 myeloid-derived suppressor cells nasopharyngeal carcinoma
Authors & Affiliations
12 authors, click to expand affiliations / ORCID
Li Ze-Lei
State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine; Sun Yat-Sen University Cancer Center (SYSUCC) ; Guangzhou, China ; Department of Biotherapy; Sun Yat-Sen University Cancer Center (SYSUCC) ; Guangzhou, China.
Ye Shu-Biao
State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine; Sun Yat-Sen University Cancer Center (SYSUCC) ; Guangzhou, China ; Department of Biotherapy; Sun Yat-Sen University Cancer Center (SYSUCC) ; Guangzhou, China.
OuYang Li-Yin
State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine; Sun Yat-Sen University Cancer Center (SYSUCC) ; Guangzhou, China ; Department of Biotherapy; Sun Yat-Sen University Cancer Center (SYSUCC) ; Guangzhou, China.
Zhang Han
State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine; Sun Yat-Sen University Cancer Center (SYSUCC) ; Guangzhou, China ; Department of Biotherapy; Sun Yat-Sen University Cancer Center (SYSUCC) ; Guangzhou, China.
Chen Yu-Shan
State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine; Sun Yat-Sen University Cancer Center (SYSUCC) ; Guangzhou, China ; Department of Radiotherapy; Sun Yat-Sen University Cancer Center (SYSUCC) ; Guangzhou, China.
He Jia
State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine; Sun Yat-Sen University Cancer Center (SYSUCC) ; Guangzhou, China ; Department of Biotherapy; Sun Yat-Sen University Cancer Center (SYSUCC) ; Guangzhou, China.
Chen Qiu-Yan
State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine; Sun Yat-Sen University Cancer Center (SYSUCC) ; Guangzhou, China ; Department of Nasopharyngeal Carcinoma; Sun Yat-Sen University Cancer Center (SYSUCC) ; Guangzhou, China.
Qian Chao-Nan
State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine; Sun Yat-Sen University Cancer Center (SYSUCC) ; Guangzhou, China ; Department of Nasopharyngeal Carcinoma; Sun Yat-Sen University Cancer Center (SYSUCC) ; Guangzhou, China.
Zhang Xiao-Shi
State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine; Sun Yat-Sen University Cancer Center (SYSUCC) ; Guangzhou, China ; Department of Biotherapy; Sun Yat-Sen University Cancer Center (SYSUCC) ; Guangzhou, China.
Cui Jun
Key Laboratory of Gene Engineering of the Ministry of Education; State Key Laboratory of Biocontrol; College of Life Sciences; Sun Yat-sen University ; Guangzhou, China.
Zeng Yi-Xin
State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine; Sun Yat-Sen University Cancer Center (SYSUCC) ; Guangzhou, China.
Li Jiang
State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine; Sun Yat-Sen University Cancer Center (SYSUCC) ; Guangzhou, China ; Department of Biotherapy; Sun Yat-Sen University Cancer Center (SYSUCC) ; Guangzhou, China.
References (58)
58 references, click to expand
  1. The mechanism of the anticancer function of M1 macrophages and their use in the clinic.
    Chin J Cancer. 2012 Dec;31(12 ):557-63 PMID: 23149314
  2. Celecoxib reduces microvessel density in patients treated with nasopharyngeal carcinoma and induces changes in gene expression.
    Ann Oncol. 2006 Nov;17(11):1625-30 PMID: 17008411
  3. Induction of myeloid-derived suppressor cells by tumor exosomes.
    Int J Cancer. 2009 Jun 1;124(11):2621-33 PMID: 19235923
  4. Celecoxib inactivates epithelial-mesenchymal transition stimulated by hypoxia and/or epidermal growth factor in colon cancer cells.
    Mol Carcinog. 2012 Oct;51(10):783-95 PMID: 21882253
  5. PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment.
    Cancer Res. 2011 Dec 15;71(24):7463-70 PMID: 22025564
  6. Blood CD33(+)HLA-DR(-) myeloid-derived suppressor cells are increased with age and a history of cancer.
    J Leukoc Biol. 2013 Apr;93(4):633-7 PMID: 23341539
  7. Cancer-related inflammation.
    J Clin Immunol. 2013 Jan;33 Suppl 1:S79-84 PMID: 23225204
  8. Myeloid-derived suppressor cell heterogeneity in human cancers.
    Ann N Y Acad Sci. 2014 Jun;1319:47-65 PMID: 24965257
  9. Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer.
    J Immunol. 2013 Apr 1;190(7):3783-97 PMID: 23440412
  10. URG11 mediates hypoxia-induced epithelial-to-mesenchymal transition by modulation of E-cadherin and beta-catenin.
    Biochem Biophys Res Commun. 2010 Jan 1;391(1):135-41 PMID: 19900406
  11. Fibrocytes represent a novel MDSC subset circulating in patients with metastatic cancer.
    Blood. 2013 Aug 15;122(7):1105-13 PMID: 23757729
  12. Interaction between tumor and immune system: the role of tumor cell biology.
    Exp Oncol. 2010 Sep;32(3):159-66 PMID: 21403611
  13. Cancer-associated fibroblasts drive the progression of metastasis through both paracrine and mechanical pressure on cancer tissue.
    Mol Cancer Res. 2012 Nov;10(11):1403-18 PMID: 23024188
  14. T-regulatory cells: key players in tumor immune escape and angiogenesis.
    Cancer Res. 2012 May 1;72(9):2162-71 PMID: 22549946
  15. Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice.
    J Clin Invest. 2011 Oct;121(10):4015-29 PMID: 21911941
  16. Phase I clinical trial of nasopharyngeal radiotherapy and concurrent celecoxib for patients with locoregionally advanced nasopharyngeal carcinoma.
    Oral Oncol. 2011 Aug;47(8):753-7 PMID: 21708478
  17. Expansion of monocytic myeloid-derived suppressor cells dampens T cell function in HIV-1-seropositive individuals.
    J Virol. 2013 Feb;87(3):1477-90 PMID: 23152536
  18. Apricoxib, a novel inhibitor of COX-2, markedly improves standard therapy response in molecularly defined models of pancreatic cancer.
    Clin Cancer Res. 2012 Sep 15;18(18):5031-42 PMID: 22829202
  19. A miR-151 binding site polymorphism in the 3'-untranslated region of the cyclin E1 gene associated with nasopharyngeal carcinoma.
    Biochem Biophys Res Commun. 2013 Mar 22;432(4):660-5 PMID: 23416081
  20. Myeloid cells obtained from the blood but not from the tumor can suppress T-cell proliferation in patients with melanoma.
    Clin Cancer Res. 2012 Oct 1;18(19):5212-23 PMID: 22837179
  21. Regulatory T cells and EBV associated malignancies.
    Int Immunopharmacol. 2009 May;9(5):590-2 PMID: 19539572
  22. Myeloid-derived suppressor cells as regulators of the immune system.
    Nat Rev Immunol. 2009 Mar;9(3):162-74 PMID: 19197294
  23. Inflammation and EMT: an alliance towards organ fibrosis and cancer progression.
    EMBO Mol Med. 2009 Sep;1(6-7):303-14 PMID: 20049734
  24. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity.
    Blood. 2008 Apr 15;111(8):4233-44 PMID: 18272812
  25. Ex vivo expansion of tumor-infiltrating lymphocytes from nasopharyngeal carcinoma patients for adoptive immunotherapy.
    Chin J Cancer. 2012 Jun;31(6):287-94 PMID: 22257383
  26. Duffy antigen receptor for chemokines (Darc) polymorphism regulates circulating concentrations of monocyte chemoattractant protein-1 and other inflammatory mediators.
    Blood. 2010 Jul 1;115(26):5289-99 PMID: 20040767
  27. COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial.
    Lancet Oncol. 2007 Oct;8(10):912-20 PMID: 17881290
  28. Tumor suppressor dual-specificity phosphatase 6 (DUSP6) impairs cell invasion and epithelial-mesenchymal transition (EMT)-associated phenotype.
    Int J Cancer. 2012 Jan 1;130(1):83-95 PMID: 21387288
  29. Myeloid derived suppressor cells in human diseases.
    Int Immunopharmacol. 2011 Jul;11(7):802-7 PMID: 21237299
  30. Epstein-Barr virus and nasopharyngeal carcinoma.
    Chin J Cancer. 2014 Dec;33(12):581-90 PMID: 25418193
  31. Locoregional radiotherapy in patients with distant metastases of nasopharyngeal carcinoma at diagnosis.
    Chin J Cancer. 2013 Nov;32(11):604-13 PMID: 24206918
  32. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein.
    J Exp Med. 2008 Sep 29;205(10):2235-49 PMID: 18809714
  33. Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression.
    Semin Cancer Biol. 2012 Aug;22(4):275-81 PMID: 22313874
  34. Mesenchymal transition and dissemination of cancer cells is driven by myeloid-derived suppressor cells infiltrating the primary tumor.
    PLoS Biol. 2011 Sep;9(9):e1001162 PMID: 21980263
  35. Intratumoral COX-2 gene expression is a predictive factor for colorectal cancer response to fluoropyrimidine-based chemotherapy.
    Clin Cancer Res. 2005 May 1;11(9):3363-8 PMID: 15867236
  36. Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells.
    Blood. 2011 Nov 17;118(20):5498-505 PMID: 21972293
  37. Cyclooxygenases in cancer: progress and perspective.
    Cancer Lett. 2004 Nov 8;215(1):1-20 PMID: 15374627
  38. Weak expression of cyclooxygenase-2 is associated with poorer outcome in endemic nasopharyngeal carcinoma: analysis of data from randomized trial between radiation alone versus concurrent chemo-radiation (SQNP-01).
    Radiat Oncol. 2009 Jul 10;4:23 PMID: 19591688
  39. CpG blocks immunosuppression by myeloid-derived suppressor cells in tumor-bearing mice.
    Clin Cancer Res. 2011 Apr 1;17(7):1765-75 PMID: 21233400
  40. Induction of myelodysplasia by myeloid-derived suppressor cells.
    J Clin Invest. 2013 Nov;123(11):4595-611 PMID: 24216507
  41. Myeloid-derived suppressor cells enhance stemness of cancer cells by inducing microRNA101 and suppressing the corepressor CtBP2.
    Immunity. 2013 Sep 19;39(3):611-21 PMID: 24012420
  42. Cyclooxygenase-2 (COX-2) up-regulation is a prognostic marker for poor clinical outcome of upper tract urothelial cancer.
    Anticancer Res. 2012 Sep;32(9):4111-6 PMID: 22993369
  43. Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy.
    Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5243-8 PMID: 17875751
  44. Wnt/Snail signaling regulates cytochrome C oxidase and glucose metabolism.
    Cancer Res. 2012 Jul 15;72 (14 ):3607-17 PMID: 22637725
  45. A role for cyclooxygenase-2 inhibitors in the prevention and treatment of cancer.
    Semin Oncol. 2002 Jun;29(3 Suppl 11):111-9 PMID: 12138405
  46. Signaling pathways involved in MDSC regulation.
    Biochim Biophys Acta. 2014 Aug;1846(1):55-65 PMID: 24727385
  47. Twist and epithelial-mesenchymal transition are induced by the EBV oncoprotein latent membrane protein 1 and are associated with metastatic nasopharyngeal carcinoma.
    Cancer Res. 2007 Mar 1;67(5):1970-8 PMID: 17332324
  48. Melanoma-educated CD14+ cells acquire a myeloid-derived suppressor cell phenotype through COX-2-dependent mechanisms.
    Cancer Res. 2013 Jul 1;73(13):3877-87 PMID: 23633486
  49. Verification of the susceptibility loci on 7p12.2, 10q21.2, and 14q11.2 in precursor B-cell acute lymphoblastic leukemia of childhood.
    Blood. 2010 Mar 4;115(9):1765-7 PMID: 20042726
  50. Myeloid-derived suppressor cells from tumor-bearing mice impair TGF-β-induced differentiation of CD4+CD25+FoxP3+ Tregs from CD4+CD25-FoxP3- T cells.
    J Leukoc Biol. 2012 Nov;92(5):987-97 PMID: 22891289
  51. Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells.
    J Immunol. 2010 Aug 15;185(4):2273-84 PMID: 20644162
  52. TGF-β-induced epithelial-mesenchymal transition: a link between cancer and inflammation.
    Semin Cancer Biol. 2012 Oct;22(5-6):455-61 PMID: 22627188
  53. The prevalence and prevention of nasopharyngeal carcinoma in China.
    Chin J Cancer. 2011 Feb;30(2):114-9 PMID: 21272443
  54. Down-regulation of PLCγ2-β-catenin pathway promotes activation and expansion of myeloid-derived suppressor cells in cancer.
    J Exp Med. 2013 Oct 21;210(11):2257-71 PMID: 24127488
  55. COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells.
    Cancer Res. 2011 Apr 1;71(7):2664-74 PMID: 21324923
  56. The role of EPH receptors in cancer-related epithelial-mesenchymal transition.
    Chin J Cancer. 2014 May;33(5):231-40 PMID: 24103789
  57. Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells.
    J Clin Invest. 2010 Feb;120(2):457-71 PMID: 20093776
  58. Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients.
    Cancer Immunol Immunother. 2012 Feb;61(2):255-63 PMID: 22120756
Article Info
Journal
Oncoimmunology
Abbr.
Oncoimmunology
ISSN
2162-4011
Published
2015-11-00
Epub
2015-00-09
Pages
e1044712
Language
English
Region
United States
NLM ID
101570526
PMCID
PMC4590030
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com